Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
Immunotherapy with immune checkpoint inhibitors (ICIs) is beneficial in treating tumors with high microsatellite instability or DNA mismatch repair deficiency (dMMR) tumors. However, the ideal therapy for patients with advanced dMMR cancer after the failure of the first ICI regimen remains unclear....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!